Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antineoplastic agent |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:CASNumber |
158440-71-6
|
| gptkbp:chemicalFormula |
C15H14O6
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:illudin_S
|
| gptkbp:discoveredBy |
MGI Pharma
|
| https://www.w3.org/2000/01/rdf-schema#label |
irofulven
|
| gptkbp:legalStatus |
investigational drug
|
| gptkbp:mechanismOfAction |
antineoplastic agent
induces DNA damage |
| gptkbp:molecularWeight |
290.27 g/mol
|
| gptkbp:sideEffect |
nausea
vomiting fatigue myelosuppression |
| gptkbp:synonym |
6-hydroxymethylacylfulvene
MGI-114 hydroxymethylacylfulvene |
| gptkbp:target |
gptkb:cancer
prostate cancer solid tumors |
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:illudin_S
|
| gptkbp:bfsLayer |
6
|